Galectin Therapeutics Inc. (GALT)
GALT Stock Price Chart
Explore Galectin Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze GALT price movements and trends.
GALT Company Profile
Discover essential business fundamentals and corporate details for Galectin Therapeutics Inc. (GALT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Sept 2002
Employees
15.00
Website
https://galectintherapeutics.comCEO
Joel Lewis CPA
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
GALT Financial Timeline
Browse a chronological timeline of Galectin Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.11.
Earnings released on 14 Aug 2025
EPS came in at -$0.12 surpassing the estimated -$0.16 by +25.00%.
Earnings released on 15 May 2025
EPS came in at -$0.15 surpassing the estimated -$0.20 by +25.00%.
Earnings released on 31 Mar 2025
EPS came in at -$0.19 falling short of the estimated -$0.16 by -18.75%, while revenue for the quarter reached $36.00K .
Earnings released on 14 Nov 2024
EPS came in at -$0.18 surpassing the estimated -$0.20 by +10.00%.
Earnings released on 13 Aug 2024
EPS came in at -$0.20 falling short of the estimated -$0.16 by -25.00%.
Earnings released on 15 May 2024
EPS came in at -$0.19 falling short of the estimated -$0.16 by -18.75%.
Earnings released on 29 Mar 2024
EPS came in at -$0.16 matching the estimated -$0.16, while revenue for the quarter reached $80.00K .
Earnings released on 13 Nov 2023
EPS came in at -$0.24 falling short of the estimated -$0.16 by -50.00%.
Earnings released on 14 Aug 2023
EPS came in at -$0.15 surpassing the estimated -$0.21 by +28.57%.
Earnings released on 15 May 2023
EPS came in at -$0.19 surpassing the estimated -$0.21 by +9.52%.
Earnings released on 30 Mar 2023
EPS came in at -$0.18 falling short of the estimated -$0.17 by -5.88%.
Earnings released on 14 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.20 by +30.00%.
Earnings released on 15 Aug 2022
EPS came in at -$0.16 surpassing the estimated -$0.19 by +15.79%.
Earnings released on 16 May 2022
EPS came in at -$0.17 falling short of the estimated -$0.10 by -70.00%.
Earnings released on 31 Mar 2022
EPS came in at -$0.13 surpassing the estimated -$0.19 by +31.58%.
Earnings released on 15 Nov 2021
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%.
Earnings released on 16 Aug 2021
EPS came in at -$0.15 surpassing the estimated -$0.18 by +16.67%.
Earnings released on 17 May 2021
EPS came in at -$0.11 surpassing the estimated -$0.17 by +35.29%.
Earnings released on 31 Mar 2021
EPS came in at -$0.14 surpassing the estimated -$0.16 by +12.50%.
Earnings released on 9 Nov 2020
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%.
GALT Stock Performance
Access detailed GALT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.